Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

November 30, 2011

View Archives Issues

  • Recommending the Appropriate Physical Activity to Your Patients

    A newly developed instrument to measure brief physical activity counseling in primary care demonstrates that physicians need to do a better job.
  • Hot Flash Treatment: 2011

    In a randomized, double-blind, placebo-controlled trial, clonidine and venlafaxine both proved superior to placebo in reducing hot flashes in breast cancer patients. The study was insufficiently powered to prove superiority of one drug over the other. However, venlafaxine produced earlier reductions and it appeared clonidine had more sustained effect (i.e., at 12 weeks of treatment).
  • Risk of Perioperative MI in Patients with Stents Undergoing Surgery

    The authors conclude that patients with coronary stents undergoing an invasive procedure are at high risk of perioperative cardiovascular and bleeding complications, and that these are associated with a high mortality.
  • Height and Cancer Risk

    From a large cohort of women followed prospectively and with an adjunct meta-analysis of existing evaluable studies, a clearly demonstrated, nearly universal (i.e., across tumor types) incremental increase in cancer incidence was observed with advancing height.
  • Tadalafil Tablets for BPH (Cialis)

    Tadalafil, Eli Lillyâs blockbuster drug for erectile dysfunction, has now been approved to treat signs and symptoms of benign prostatic hyperplasia. Tadalafil is the first drug of its class to be approved for this indication.
  • Clinical Briefs By Louis Kuritzky, MD

    Recent retrospective studies in Europe have created concern because of an observed increased risk of cancer (hazard ratio = 1.55) in users of insulin glargine (GLAR) compared to nonusers.